Similarly, ~ 50% cases of high-grade ovarian cancers carry BRCA1 and BRCA2 mutations, causing high-incidence of homologous recombination deficiency (HRD) [14–16]. This evidence concerns the gene BRCA2 and ovarian carcinoma.